Research Triangle Park, NC-based venture capital firm Hatteras Venture Partners held the first closing of its Fund V at more than $90m.
Hatteras Venture Partners V (HVP V), which has a final target of $150m, will focus on investing in human health companies, ranging from biopharmaceuticals and medical devices to diagnostics and health care IT.
It focuses on science and technology from leading academic centers and the active involvement of the team of entrepreneurs and operators. In addition, HVP V will leverage its limited partner relationships with institutions such as the University of North Carolina at Chapel Hill, GSK, Malin, Laboratory Corporation of America Holdings, Alexandria Venture Investments, and other financial investors.
The firm will allocate up to 20% of HVP V to seed-stage projects and companies. With the closing of HVP V, Christy Shaffer, who served as Managing Director of Hatteras Discovery, has become a General Partner working with Bob Ingram and Clay Thorp.
In addition, Hatteras has entered a partnership with Malin Corporation PLC to bolster its strategic partnering capacity.